The HDPCR NSCLC panel was designed for high inclusivity of highly variable targets like EGFR Exon 20 insertions (89%), EGFR Exon 19 deletions (99%), and RNA fusions (95–100%). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.